171 related articles for article (PubMed ID: 15449043)
1. Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer.
Russell PJ; Ow KT; Tam PN; Juarez J; Kingsley EA; Qu CF; Li Y; Cozzi PJ; Martiniello-Wilks R
Cancer Immunol Immunother; 2004 Nov; 53(11):995-1004. PubMed ID: 15449043
[TBL] [Abstract][Full Text] [Related]
2. Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody.
Carter T; Sterling-Levis K; Ow K; Doughty L; Hattarki M; Shapira D; Hewish D; Kortt AA; Russell PJ
Cancer Immunol Immunother; 2004 Jun; 53(6):533-42. PubMed ID: 14722669
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of the expression of prostate tumor-association markers in the nude mouse human prostate carcinoma heterotransplant lines PC-82, PC-EW, and PC-EG.
Wright GL; Haley CL; Csapo Z; van Steenbrugge GJ
Prostate; 1990; 17(4):301-16. PubMed ID: 1701249
[TBL] [Abstract][Full Text] [Related]
4. Expression of the prostate-specific membrane antigen.
Israeli RS; Powell CT; Corr JG; Fair WR; Heston WD
Cancer Res; 1994 Apr; 54(7):1807-11. PubMed ID: 7511053
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers.
Tacha D; Bremer R; Haas T; Qi W
Arch Pathol Lab Med; 2014 Oct; 138(10):1358-64. PubMed ID: 24528495
[TBL] [Abstract][Full Text] [Related]
6. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
Li Y; Abbas Rizvi SM; Blair nee Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJ; Allen BJ
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):896-908. PubMed ID: 15465208
[TBL] [Abstract][Full Text] [Related]
7. MRl of prostate cancer antigen expression for diagnosis and immunotherapy.
Ren J; Wang F; Wei G; Yang Y; Liu Y; Wei M; Huan Y; Larson AC; Zhang Z
PLoS One; 2012; 7(6):e38350. PubMed ID: 22761679
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines.
Zhau HE; Wan DS; Zhou J; Miller GJ; von Eschenbach AC
Mol Carcinog; 1992; 5(4):320-7. PubMed ID: 1353965
[TBL] [Abstract][Full Text] [Related]
9. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23.
Subong EN; Shue MJ; Epstein JI; Briggman JV; Chan PK; Partin AW
Prostate; 1999 Jun; 39(4):298-304. PubMed ID: 10344220
[TBL] [Abstract][Full Text] [Related]
12. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues.
Wu GJ; Varma VA; Wu MW; Wang SW; Qu P; Yang H; Petros JA; Lim SD; Amin MB
Prostate; 2001 Sep; 48(4):305-15. PubMed ID: 11536311
[TBL] [Abstract][Full Text] [Related]
13. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
15. [Development and characterization of a monoclonal antibody which recognizes a new prostate-organ specific antigen].
Ka S; Eto H; Arakawa S; Kamidono S
Nihon Hinyokika Gakkai Zasshi; 1999 Sep; 90(9):790-7. PubMed ID: 10517088
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen.
Carroll AM; Zalutsky M; Schatten S; Bhan A; Perry LL; Sobotka C; Benacerraf B; Greene MI
Clin Immunol Immunopathol; 1984 Nov; 33(2):268-81. PubMed ID: 6488592
[TBL] [Abstract][Full Text] [Related]
17. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
18. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
Saito S; Egawa S; Endoh M; Ueno S; Ito A; Numahata K; Satoh M; Kuwao S; Baba S; Hakomori S; Arai Y
Int J Cancer; 2005 May; 115(1):105-13. PubMed ID: 15704108
[TBL] [Abstract][Full Text] [Related]
19. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA.
Banerjee AG; Liu J; Yuan Y; Gopalakrishnan VK; Johansson SL; Dinda AK; Gupta NP; Trevino L; Vishwanatha JK
Mol Cancer; 2003 Oct; 2():34. PubMed ID: 14613585
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
